Dr. Finn on the Promise of Regorafenib for the Treatment of HCC

Richard Finn, MD
Published: Saturday, Jan 21, 2017


Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, discusses the promise of regorafenib (Stivarga) for the treatment of hepatocellular carcinoma (HCC), as seen in the phase III RESORCE trial. 

For the first time, a study has shown an improvement in median overall survival, from 7.8 months in the control arm to 10.6 months in patients who received sorafenib (Nexavar) followed by regorafenib. This represents a 37% decrease in the risk of death, Finn says.

Regorafenib is still awaiting full regulatory approval for this indication, but based on the data seen thus far, this should become the new standard of treatment for patients progressing on sorafenib, Finn says.

Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, discusses the promise of regorafenib (Stivarga) for the treatment of hepatocellular carcinoma (HCC), as seen in the phase III RESORCE trial. 

For the first time, a study has shown an improvement in median overall survival, from 7.8 months in the control arm to 10.6 months in patients who received sorafenib (Nexavar) followed by regorafenib. This represents a 37% decrease in the risk of death, Finn says.

Regorafenib is still awaiting full regulatory approval for this indication, but based on the data seen thus far, this should become the new standard of treatment for patients progressing on sorafenib, Finn says.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Frontiers in Immuno-Oncology for Microsatellite Instability-High CancersAug 29, 20182.0
Community Practice Connections™: 1st Annual School of Nursing Oncology™Oct 31, 20181.5
Publication Bottom Border
Border Publication
x